FDA Approves Atacicept for IgA Nephropathy - Quiz - MDSpire

FDA Approves Atacicept for IgA Nephropathy

The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.

  • By

  • Kathryn Wighton

  • July 7, 2026

  • 3 min

Share

Original Source(s)

FDA Approves Atacicept for IgA Nephropathy

  • by Kathryn Wighton

  • July 7, 2026

Related Content

Measles-Related Vitamin A Searches Rise

Google Trends data showed increased US search interest in vitamin A and cod liver oil during the 2025 measles outbreak, but normalized search data cannot determine actual product use, dosing behavior, or harms.

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Oral Carbapenem Wins FDA Approval for cUTIs

Tebipenem pivoxil was noninferior to intravenous imipenem-cilastatin in hospitalized adults.